Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Open access

Abstract

Immune checkpoint inhibitors have been successful across several tumor types; however, their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where <10% of patients show long-term responses. To understand the molecular determinants of immunotherapeutic response in GBM, we longitudinally profiled 66 patients, including 17 long-term responders, during standard therapy and after treatment with PD-1 inhibitors (nivolumab or pembrolizumab). Genomic and transcriptomic analysis revealed a significant enrichment of PTEN mutations associated with immunosuppressive expression signatures in non-responders, and an enrichment of MAPK pathway alterations (PTPN11, BRAF) in responders. Responsive tumors were also associated with branched patterns of evolution from the elimination of neoepitopes as well as with differences in T cell clonal diversity and tumor microenvironment profiles. Our study shows that clinical response to anti-PD-1 immunotherapy in GBM is associated with specific molecular alterations, immune expression signatures, and immune infiltration that reflect the tumor's clonal evolution during treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0349-y

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 923

Metadata

Authors
Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., Filip, I., Orenbuch, R., Goetz, M., Yamaguchi, J. T., Cloney, M., Horbinski, C., Lukas, R. V., Raizer, J., Rae, A. I., Yuan, J., Canoll, P., Bruce, J. N., Saenger, Y. M., Sims, P., Iwamoto, F. M., Sonabend, A. M., & Rabadan, R.
Affiliations
  • Columbia University (US)
  • Columbia University Irving Medical Center (US)
  • University of North Carolina at Chapel Hill (US)
  • Northwestern University (US)
  • Oregon Health & Science University (US)
Corresponding author
  • Iwamoto, Fabio M.
  • Sonabend, Adam M.
Venue
Nature Medicine
Published
2019-02-11
Volume
25
Issue
3
Pages
462-469
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2911871569
Cited by
903
References
60
Citations by year
2026: 73 · 2025: 119 · 2024: 125 · 2023: 119 · 2022: 165 · 2021: 146 · 2020: 110 · 2019: 45
FWCI
49.53
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • UNC Libraries
Funders
  • National Institutes of Health (UL1TR001422, DP5OD021356, UL1TR001873, TL1TR001875)
  • Directorate for Mathematical and Physical Sciences
  • National Cancer Institute (R01CA185486, R01CA179044, U54CA193313, P50CA221747, P30CA060553)
  • National Institute of General Medical Sciences (T32GM007367)
  • National Institute of Neurological Disorders and Stroke (R01NS102669, R01NS103473)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
glioblastoma, anti-PD-1 therapy, immune checkpoint inhibitors, nivolumab, pembrolizumab, treatment response prediction, PTEN mutation, MAPK pathway alterations, tumor clonal evolution, neoantigens, tumor microenvironment, immune cell infiltration, patient stratification
MeSH terms
Antineoplastic Agents, Immunological, Nivolumab, Adult, Aged, Brain Neoplasms, Female, Glioblastoma, Humans, Immune Tolerance, Longitudinal Studies, Male, Middle Aged, Mutation, T-Lymphocytes, Treatment Outcome, Gene Expression Profiling, Genomics, Proto-Oncogene Proteins B-raf, PTEN Phosphohydrolase, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Young Adult, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. https://app.cochat.ai/papers/10.1038/s41591-019-0349-y
The paper
Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., Filip, I., Orenbuch, R., Goetz, M., Yamaguchi, J. T., Cloney, M., Horbinski, C., Lukas, R. V., Raizer, J., Rae, A. I., . . . Rabadan, R. (2019). Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nature Medicine. https://doi.org/10.1038/s41591-019-0349-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.